ProCE Banner Activity

KEYNOTE-426: Preplanned Final Analysis of First-line Pembrolizumab + Axitinib vs Sunitinib for Advanced Clear-Cell Renal Cell Carcinoma

Slideset Download
Conference Coverage
Pembrolizumab plus axitinib continued to demonstrate superior efficacy compared with sunitinib monotherapy in patients with previously untreated advanced clear-cell RCC with a median follow-up of 42 months.

Released: June 11, 2021

Expiration: June 10, 2022

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie

Amgen, Inc.

AstraZeneca

Bristol Myers Squibb

Daiichi Sankyo, Inc.

Exelixis

Gilead Sciences, Inc.

GlaxoSmithKline

Ipsen Biopharmaceuticals Inc

Merck Sharp & Dohme Corp.

Novartis Pharmaceuticals Corporation

Pfizer, Inc.

Pharmacyclics LLC an AbbVie Company and Janssen Biotech Inc

Sanofi Genzyme